Specter, who switched from Republican to Democratic in 2009 after he voted for President Obama's economic stimulus package, touted his support for abortion rights in previous campaigns (Levy, AP/Philadelphia Inquirer, 5/12). However, NARAL officials noted that Specter supported President George W. Bush's two Supreme Court nominees -- Chief Justice John Roberts and Justice Samuel Alito -- while he was a Republican on the Senate Judiciary Committee (Becker, "The Caucus," New York Times, 5/12). Elizabeth Shipp, NARAL's political director, said the "court is more hostile to reproductive rights because of those two, and we have Arlen Specter to thank for it."
Shipp added that Sestak's voting record on abortion-rights issues during his two terms in the House makes clear his support for abortion rights. She said that Specter tends to vote for abortion rights when it is convenient, not because of his convictions (Levy, AP/Philadelphia Inquirer, 5/12).
NARAL President Nancy Keenan said, "Many Pennsylvanians are under the impression that Arlen Specter might be a reliable pro-choice voice, but his record says otherwise." She added that Sestak is "a strong voice for women's freedom and privacy."
According to Politico, NARAL's political action committee will donate $5,000 to Sestak's campaign and mobilize its supporters on his behalf (Taylor, Politico, 5/12). Group officials said they have sent e-mail messages to their 250,000 Pennsylvania members to encourage support for Sestak (AP/Philadelphia Inquirer, 5/12).
In response to the endorsement, Specter's campaign released a statement from longtime Pennsylvania abortion-rights advocate Morgan Plant, who supports Specter. Plant said, "With all the threats to choice which still abound, it seems foolish to me to expend pro-choice resources against Specter." She added that "as a strongly pro-choice woman," she "still trust[s] Sen. Specter to preserve and protect a woman's right to choose" ("The Caucus," New York Times, 5/12).
According to the AP/Inquirer, Sestak received perfect scores from NARAL on his abortion-rights voting record in 2007 and 2009, the only two years he was scored. Specter's received perfect scores in 2007 and 2008, and a score of 90% in 2009. However, he received a 21% in 2003, a zero in 2004 and a 20% in 2005.
Polls Shows Close Race
Meanwhile, a Quinnipiac University poll released Wednesday showed that Sestak has nearly closed the 21-point lead Specter held in an April 8 poll. The new poll -- a telephone survey of 945 likely primary voters -- found that 44% of respondents supported Specter, 42% supported Sestak and 14% were undecided. The survey was conducted May 5 through May 10 and had a sampling error of plus or minus 3.2 percentage points.
The AP/Philadelphia Inquirer reports that Sestak received a boost from "a wave of anti-incumbent sentiment" and a television ad linking Specter with Bush. Specter, meanwhile, has the support of the White House and on Tuesday launched a new TV ad featuring the president (AP/Philadelphia Inquirer, 5/12).
Reprinted with kind permission from nationalpartnership. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.
© 2010 The Advisory Board Company. All rights reserved.
вторник, 31 января 2012 г.
NARAL Endorses Rep. Sestak In Close Primary Against Sen. Specter
NARAL Pro-Choice America on Wednesday endorsed Pennsylvania Rep. Joe Sestak over five-term incumbent Sen. Arlen Specter in the Democratic primary, which is "too close to call" ahead of Tuesday's vote, the AP/Philadelphia Inquirer reports.
вторник, 24 января 2012 г.
UQ Study Shows Childhood Sexual Abuse Has Lasting Effects
A University of Queensland study has found that women who experience certain types of sexual abuse (penetrative) in their youth are at increased odds of being overweight by the age of 21.
The study, which drew from the responses of 1273 men and 1305 women aged 21 years, found while there was a marked association between severe childhood sexual abuse (CSA) and greater body mass index (BMI) among women, this association did not hold for men.
Lead researcher Dr Abdullah Al Mamun from the University's School of Population Health said the study provided an important insight into possible gender differences in the way men and women deal with trauma and also gave some credence to previous theories about a relationship between CSA and greater BMI.
Dr Mamun said it had previously been posited that "comfort eating" might result as an "adaptive function" after CSA or that individuals may purposefully try to alter their lifestyles to increase weight as a means of protecting themselves from further abuse.
"The gender difference may reflect differences between women and men in the relationship between psychological trauma and body image," he said.
The research was conducted as part of the Mater-University Study of Pregnancy (MUSP), a longitudinal study of over 7000 mothers and their children born at Brisbane's Mater Hospital in 1981-83.
Dr Mamun said the large scale of the study, along with its sampling of both men and women, went a long way to address many of the limitations of previous studies.
"Most of the previous studies that have claimed a possible association between CSA and adult obesity are methodically weak with respect to providing causal inference," Dr Mamun said.
"The majority have been conducted on clinically obese populations in which a higher than expected proportion report CSA; other studies have been men and women only and therefore, cannot provide information on this association in men; and finally, most studies, by epidemiological standards, have been relatively small," he said.
"This study is a community-based prospective birth cohort involving repeated assessments of children before the disclosure of CSA, making it possible to take into account prospectively measured potential confounders of any association of CSA and BMI.
"Further, the study includes both men and women and the large sample size permits assessment of gender differences in the association between CSA and BMI."
Dr Mamun said the study had important implications for clinical professionals and their treatment of patients who have suffered CSA.
"The study's findings highlight the need for clinicians to be aware not only of the long-term mental health sequelae of child sexual abuse but also of the possibility of risk to physical health."
"Large prospective studies are, however, required to confirm our findings and to explore the possible mechanisms for any association."
Looking for an expert? Contact details for more than 1500 UQ academics and researchers who can provide media with expert comment are available online at uq.edu.au/uqexperts.
The University of Queensland, Brisbane Australia
The study, which drew from the responses of 1273 men and 1305 women aged 21 years, found while there was a marked association between severe childhood sexual abuse (CSA) and greater body mass index (BMI) among women, this association did not hold for men.
Lead researcher Dr Abdullah Al Mamun from the University's School of Population Health said the study provided an important insight into possible gender differences in the way men and women deal with trauma and also gave some credence to previous theories about a relationship between CSA and greater BMI.
Dr Mamun said it had previously been posited that "comfort eating" might result as an "adaptive function" after CSA or that individuals may purposefully try to alter their lifestyles to increase weight as a means of protecting themselves from further abuse.
"The gender difference may reflect differences between women and men in the relationship between psychological trauma and body image," he said.
The research was conducted as part of the Mater-University Study of Pregnancy (MUSP), a longitudinal study of over 7000 mothers and their children born at Brisbane's Mater Hospital in 1981-83.
Dr Mamun said the large scale of the study, along with its sampling of both men and women, went a long way to address many of the limitations of previous studies.
"Most of the previous studies that have claimed a possible association between CSA and adult obesity are methodically weak with respect to providing causal inference," Dr Mamun said.
"The majority have been conducted on clinically obese populations in which a higher than expected proportion report CSA; other studies have been men and women only and therefore, cannot provide information on this association in men; and finally, most studies, by epidemiological standards, have been relatively small," he said.
"This study is a community-based prospective birth cohort involving repeated assessments of children before the disclosure of CSA, making it possible to take into account prospectively measured potential confounders of any association of CSA and BMI.
"Further, the study includes both men and women and the large sample size permits assessment of gender differences in the association between CSA and BMI."
Dr Mamun said the study had important implications for clinical professionals and their treatment of patients who have suffered CSA.
"The study's findings highlight the need for clinicians to be aware not only of the long-term mental health sequelae of child sexual abuse but also of the possibility of risk to physical health."
"Large prospective studies are, however, required to confirm our findings and to explore the possible mechanisms for any association."
Looking for an expert? Contact details for more than 1500 UQ academics and researchers who can provide media with expert comment are available online at uq.edu.au/uqexperts.
The University of Queensland, Brisbane Australia
вторник, 17 января 2012 г.
Supermodel Beverly Johnson Speaks Out To End Silence About Uterine Fibroids
Supermodel Beverly Johnson is on a mission to get women to Ask 4 questions and Tell 4 or more others about a health condition faced by up to 75 percent of all women in the U.S. (1): uterine fibroids. Although uterine fibroids are common, many women remain uninformed about this condition, and a majority wait up to a year before finding treatment, often despite pain, heavy bleeding and weight gain. Beverly did, and now she is sharing her story to ensure that other women not only avoid silent suffering, but actively seek suitable treatment options now. Women can read Beverly's personal story and learn more about uterine fibroids and their treatment at ask4tell4.
"It is my personal mission to help ensure that women are informed about uterine fibroids and feel empowered, if they think they have fibroids or are diagnosed with them, to talk with their healthcare providers about their treatment options," said Beverly Johnson. "When I was diagnosed with uterine fibroids, I didn't know a lot about the condition, and as a result I suffered for a long time, both physically and emotionally. My hope is that women will not be embarrassed to talk about uterine fibroids or afraid to discuss treatment options with their doctors."
Lack of information about uterine fibroids and treatment options can have serious consequences for a woman's health and quality of life. According to a national survey*, less than half of the women surveyed could identify non-surgical and uterine sparing options for fibroids. Left untreated, fibroids can cause heavy bleeding, pelvic pain, enlargement of the abdomen, and can lead to reproductive problems.
"Many women silently accept symptoms of uterine fibroids as an unfortunate fact of life, or the result of aging. Others hesitate to discuss their condition because they fear that major surgery is their only treatment option. It is not," said Linda Bradley, M.D., Chair of the OB/GYN Section of the National Medical Association and Vice Chair of Obstetrics, Gynecology, and Women's Health Institute at the Cleveland Clinic. "Women who have uterine fibroid tumors should know that many treatments are available that can ease their pain and symptoms. While hysterectomy has been the standard surgical treatment for many years, technology has advanced and a number of clinically-proven, non-surgical and uterine-sparing procedures are widely available."
Beverly's Story
Beverly developed uterine fibroids in her 30s, and for years faced symptoms including heavy bleeding, abdominal pain, fatigue and emotional stress. After attempting to manage her symptoms with diet and acupuncture, she consulted with two doctors; both recommended she get a hysterectomy. Unfortunately, Beverly didn't fully understand what a hysterectomy entailed, and she suffered severe complications from the surgery. It took several years of recovery and hormone replacement therapy for her to get her body and life back in balance.
Beverly hopes her willingness to share her story will encourage women to learn about the variety of uterine fibroid treatment options available today, so they can play a more active role in talking with their doctors to select the treatment that best suits their condition and lifestyle.
Ask4tell4
Beverly's new Web site, Ask4tell4, highlights the four questions she thinks all women should ask themselves and their healthcare provider about uterine fibroids, whether they currently have the condition or not. The site also includes the answers to these questions and information about a variety of treatment options that wll help them have a more informed discussion with their doctor. Additionally, women can join Beverly's cause by sharing the information with four or more of their friends or family members through an instant email message sent from the Web site.
The Ask4Tell4 campaign is sponsored by BioSphere Medical, Inc. BioSphere is a pioneer in commercializing minimally invasive therapeutic applications based on proprietary bioengineered microsphere technology. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE.
*Survey cited was also sponsored by BioSphere and conducted by Caravan Research Corporation. The survey was conducted via telephone to 1,000 women during July 2007.
(1) Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7
Ask4tell4
"It is my personal mission to help ensure that women are informed about uterine fibroids and feel empowered, if they think they have fibroids or are diagnosed with them, to talk with their healthcare providers about their treatment options," said Beverly Johnson. "When I was diagnosed with uterine fibroids, I didn't know a lot about the condition, and as a result I suffered for a long time, both physically and emotionally. My hope is that women will not be embarrassed to talk about uterine fibroids or afraid to discuss treatment options with their doctors."
Lack of information about uterine fibroids and treatment options can have serious consequences for a woman's health and quality of life. According to a national survey*, less than half of the women surveyed could identify non-surgical and uterine sparing options for fibroids. Left untreated, fibroids can cause heavy bleeding, pelvic pain, enlargement of the abdomen, and can lead to reproductive problems.
"Many women silently accept symptoms of uterine fibroids as an unfortunate fact of life, or the result of aging. Others hesitate to discuss their condition because they fear that major surgery is their only treatment option. It is not," said Linda Bradley, M.D., Chair of the OB/GYN Section of the National Medical Association and Vice Chair of Obstetrics, Gynecology, and Women's Health Institute at the Cleveland Clinic. "Women who have uterine fibroid tumors should know that many treatments are available that can ease their pain and symptoms. While hysterectomy has been the standard surgical treatment for many years, technology has advanced and a number of clinically-proven, non-surgical and uterine-sparing procedures are widely available."
Beverly's Story
Beverly developed uterine fibroids in her 30s, and for years faced symptoms including heavy bleeding, abdominal pain, fatigue and emotional stress. After attempting to manage her symptoms with diet and acupuncture, she consulted with two doctors; both recommended she get a hysterectomy. Unfortunately, Beverly didn't fully understand what a hysterectomy entailed, and she suffered severe complications from the surgery. It took several years of recovery and hormone replacement therapy for her to get her body and life back in balance.
Beverly hopes her willingness to share her story will encourage women to learn about the variety of uterine fibroid treatment options available today, so they can play a more active role in talking with their doctors to select the treatment that best suits their condition and lifestyle.
Ask4tell4
Beverly's new Web site, Ask4tell4, highlights the four questions she thinks all women should ask themselves and their healthcare provider about uterine fibroids, whether they currently have the condition or not. The site also includes the answers to these questions and information about a variety of treatment options that wll help them have a more informed discussion with their doctor. Additionally, women can join Beverly's cause by sharing the information with four or more of their friends or family members through an instant email message sent from the Web site.
The Ask4Tell4 campaign is sponsored by BioSphere Medical, Inc. BioSphere is a pioneer in commercializing minimally invasive therapeutic applications based on proprietary bioengineered microsphere technology. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE.
*Survey cited was also sponsored by BioSphere and conducted by Caravan Research Corporation. The survey was conducted via telephone to 1,000 women during July 2007.
(1) Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100-7
Ask4tell4
вторник, 10 января 2012 г.
Aboriginal And Torres Strait Islander Women's Health - Australia
This paper summarizes the recent 'Indigenous Women's Health' meeting outcomes and gives recommendations on how the Royal Australian and New Zealand College of Obstetricians and Gynecologists (RANZCOG) can improve the health of Aboriginal and Torres Strait Islander women and infants.
The conference covered a wide range of topics including improving cultural competence among non-indigenous providers, provision of culturally safe health care, recognition of the roles of Aboriginal health workers, effective collaboration and the developmental origins of health and disease in an indigenous context.
By raising many important issues onto the agenda, the meeting allowed these issues to be followed with some real and positive actions.
"Aboriginal and Torres Strait Islander Women's Health: Acting Now for a Healthy Future"
Boyle J, Rumbold A.R, Clarke M, Hughes C and Kane S.
Click here to view abstract online.
Australian and New Zealand Journal of Obstetrics and Gynaecology (Volume 48 Issue 6, December 2008)
ranzcog.edu.au/publications/anzjog.shtml
The conference covered a wide range of topics including improving cultural competence among non-indigenous providers, provision of culturally safe health care, recognition of the roles of Aboriginal health workers, effective collaboration and the developmental origins of health and disease in an indigenous context.
By raising many important issues onto the agenda, the meeting allowed these issues to be followed with some real and positive actions.
"Aboriginal and Torres Strait Islander Women's Health: Acting Now for a Healthy Future"
Boyle J, Rumbold A.R, Clarke M, Hughes C and Kane S.
Click here to view abstract online.
Australian and New Zealand Journal of Obstetrics and Gynaecology (Volume 48 Issue 6, December 2008)
ranzcog.edu.au/publications/anzjog.shtml
вторник, 3 января 2012 г.
Test Score Reveals Which Breast Cancer Patients Can Avoid Chemo
A new prospective study shows a 21-gene test of a patient's breast cancer tumor may change doctor and patient treatment decisions, including the need for chemotherapy.
Researchers at Loyola University Health System, Maywood, Ill., presented the findings at the American Society of Clinical Oncology annual meeting.
Participating in the study were 89 patients with early-stage, node-negative, estrogen-receptor-positive breast cancer and 17 medical oncologists at four different centers nationally. Each patient had the multi-gene expression test taken from a tissue sample of the tumor, which produces a very specific, molecular fingerprint of the cancer.
The Oncotype DX™ Recurrence Score™ tells the chance of distant recurrence of the cancer over 10 years if only tamoxifen is given and provides the likelihood of benefit from chemotherapy. Treatment decisions are based on whether the score is low, medium or high. Participating physicians and patients were surveyed regarding their treatment decision before the test was sent and again after discussion of the test results.
"This test score changed the treatment decisions of 31.5 percent of medical oncologists and 27 percent of patients," said senior study investigator Dr. Kathy S. Albain, director, breast clinical research program; and co-director, the multidisciplinary breast oncology center at the Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.
"It's a new dimension of tailoring treatment to the individual," said Albain, professor, division of hematology/oncology, department of medicine, Loyola University Chicago Stritch School of Medicine, Maywood. "The study proves for the first time that the score impacts our decision-making as oncologists.
"Test results reduced the number of women who had to undergo chemotherapy," said Albain. In 22.5 percent of the cases, the doctors said the patient could avoid chemotherapy. In 76 percent of the cases, oncologists indicated they had increased confidence in their treatment decisions after reviewing the test results with their patients.
The majority of patients, 83 percent, reported that this test influenced their treatment decisions. "The test score provides patients with more certainty that they are taking the right steps for their specific cancer," said Albain, also director of Loyola's thoracic oncology program.
Colleen G., 40, was relieved that her test results showed chemotherapy was probably not necessary. Diagnosed with breast cancer at 39, she would ordinarily undergo lumpectomy followed by radiation, chemotherapy and tamoxifen, based on her young age.
"My test results showed that the breast cancer is not as likely to recur, so I felt comfortable opting not to have chemo," said Colleen, a mother of two children. "That gave me peace of mind and confidence in my decision."
Colleen has had two mammograms since her treatment as well as close examinations and follow-up. Today, she remains a cancer-survivor, free of recurrence in the breast or elsewhere in her body.
The majority of the patients studied reported they were glad to have the opportunity to take the test. It must be ordered by a physician.
This investigator-initiated study was funded by an unrestricted grant from Genomic Health, Inc.
Co-authors of the study, with Albain, are lead investigator Dr. Shelly S. Lo, John Norton and Patricia B. Mumby, Ph.d., from Loyola; Dr. Jeffrey Smerage and Dr. Daniel Hayes from University of Michigan, Ann Arbor; Dr. Joseph Kash, Edward Hospital, Naperville, Ill.; Dr. Helen K. Chew, University of California- Davis, Sacramento; and Dr. Andrew Epstein, Mount Sinai Medical Center, New York.
Visit LoyolaMedicine for more information.
More than 29,000 oncology professionals are expected to attend the 43rd annual meeting of the American Society of Clinical Oncology at McCormick Place, Chicago, which runs through June 5, 2007.
Loyola University Health System, a wholly owned subsidiary of Loyola University Chicago (LUC), includes the private teaching hospital at Loyola University Medical Center (LUMC),14 specialty and primary care centers in the western and southwestern suburbs, the Loyola Ambulatory Surgery Center at Oakbrook and the Loyola Oakbrook Terrace Imaging Center; and serves as co-owner-operator of RML Specialty Hospital, a long-term acute hospital specializing in ventilation weaning and other medically complex patients in suburban Hinsdale, Ill. Loyola is nationally recognized for its specialty care and groundbreaking research in cancer, neurological disorders, neonatology and the treatment of heart disease. The 61-acre medical center campus in Maywood, Ill., includes the 589-licensed bed Loyola University Hospital with a Level I trauma center, the region's largest burn unit, one of the Midwest's most comprehensive organ transplant programs, the Russo Surgical Pavilion and the Ronald McDonald® Children's Hospital of LUMC. Also on campus are Loyola's Center for Heart & Vascular Medicine, the Cardinal Bernardin Cancer Center, Loyola Outpatient Center and LUC Stritch School of Medicine. The medical school includes the Cardiovascular Institute, Oncology Institute, Burn & Shock Trauma Institute, Neuroscience Institute and the Neiswanger Institute for Bioethics and Health Policy.
Loyola University Health System
2160 S. First Ave.
Maywood, IL 60153
United States
luhs
Researchers at Loyola University Health System, Maywood, Ill., presented the findings at the American Society of Clinical Oncology annual meeting.
Participating in the study were 89 patients with early-stage, node-negative, estrogen-receptor-positive breast cancer and 17 medical oncologists at four different centers nationally. Each patient had the multi-gene expression test taken from a tissue sample of the tumor, which produces a very specific, molecular fingerprint of the cancer.
The Oncotype DX™ Recurrence Score™ tells the chance of distant recurrence of the cancer over 10 years if only tamoxifen is given and provides the likelihood of benefit from chemotherapy. Treatment decisions are based on whether the score is low, medium or high. Participating physicians and patients were surveyed regarding their treatment decision before the test was sent and again after discussion of the test results.
"This test score changed the treatment decisions of 31.5 percent of medical oncologists and 27 percent of patients," said senior study investigator Dr. Kathy S. Albain, director, breast clinical research program; and co-director, the multidisciplinary breast oncology center at the Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill.
"It's a new dimension of tailoring treatment to the individual," said Albain, professor, division of hematology/oncology, department of medicine, Loyola University Chicago Stritch School of Medicine, Maywood. "The study proves for the first time that the score impacts our decision-making as oncologists.
"Test results reduced the number of women who had to undergo chemotherapy," said Albain. In 22.5 percent of the cases, the doctors said the patient could avoid chemotherapy. In 76 percent of the cases, oncologists indicated they had increased confidence in their treatment decisions after reviewing the test results with their patients.
The majority of patients, 83 percent, reported that this test influenced their treatment decisions. "The test score provides patients with more certainty that they are taking the right steps for their specific cancer," said Albain, also director of Loyola's thoracic oncology program.
Colleen G., 40, was relieved that her test results showed chemotherapy was probably not necessary. Diagnosed with breast cancer at 39, she would ordinarily undergo lumpectomy followed by radiation, chemotherapy and tamoxifen, based on her young age.
"My test results showed that the breast cancer is not as likely to recur, so I felt comfortable opting not to have chemo," said Colleen, a mother of two children. "That gave me peace of mind and confidence in my decision."
Colleen has had two mammograms since her treatment as well as close examinations and follow-up. Today, she remains a cancer-survivor, free of recurrence in the breast or elsewhere in her body.
The majority of the patients studied reported they were glad to have the opportunity to take the test. It must be ordered by a physician.
This investigator-initiated study was funded by an unrestricted grant from Genomic Health, Inc.
Co-authors of the study, with Albain, are lead investigator Dr. Shelly S. Lo, John Norton and Patricia B. Mumby, Ph.d., from Loyola; Dr. Jeffrey Smerage and Dr. Daniel Hayes from University of Michigan, Ann Arbor; Dr. Joseph Kash, Edward Hospital, Naperville, Ill.; Dr. Helen K. Chew, University of California- Davis, Sacramento; and Dr. Andrew Epstein, Mount Sinai Medical Center, New York.
Visit LoyolaMedicine for more information.
More than 29,000 oncology professionals are expected to attend the 43rd annual meeting of the American Society of Clinical Oncology at McCormick Place, Chicago, which runs through June 5, 2007.
Loyola University Health System, a wholly owned subsidiary of Loyola University Chicago (LUC), includes the private teaching hospital at Loyola University Medical Center (LUMC),14 specialty and primary care centers in the western and southwestern suburbs, the Loyola Ambulatory Surgery Center at Oakbrook and the Loyola Oakbrook Terrace Imaging Center; and serves as co-owner-operator of RML Specialty Hospital, a long-term acute hospital specializing in ventilation weaning and other medically complex patients in suburban Hinsdale, Ill. Loyola is nationally recognized for its specialty care and groundbreaking research in cancer, neurological disorders, neonatology and the treatment of heart disease. The 61-acre medical center campus in Maywood, Ill., includes the 589-licensed bed Loyola University Hospital with a Level I trauma center, the region's largest burn unit, one of the Midwest's most comprehensive organ transplant programs, the Russo Surgical Pavilion and the Ronald McDonald® Children's Hospital of LUMC. Also on campus are Loyola's Center for Heart & Vascular Medicine, the Cardinal Bernardin Cancer Center, Loyola Outpatient Center and LUC Stritch School of Medicine. The medical school includes the Cardiovascular Institute, Oncology Institute, Burn & Shock Trauma Institute, Neuroscience Institute and the Neiswanger Institute for Bioethics and Health Policy.
Loyola University Health System
2160 S. First Ave.
Maywood, IL 60153
United States
luhs
Подписаться на:
Комментарии (Atom)